Roche signs $2.5B deal with Boston’s Monte Rosa Therapeutics

A three-year-old startup behind so-called "molecular glues" just gained new firepower in the form of a Big Pharma partnership.

Previous BNY Mellon on track to outperform 4% expense growth target, 'bend the cost curve further'
Next Tower Health's 'diminished financial flexibility' cited in latest bond rating downgrade